Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT00210379 Completed - Lymphoma, B Cell Clinical Trials

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Start date: November 2000
Phase: Phase 2
Study type: Interventional

The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy

NCT ID: NCT00210366 Terminated - Lymphoma, B-Cell Clinical Trials

Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

Start date: November 2004
Phase: Phase 2
Study type: Interventional

The main objective of the trial is to assess the therapeutic activity of idarubicin as salvage treatment in patients with recurrent or progressive lymphoma in the central nervous system.

NCT ID: NCT00210340 Withdrawn - Lymphoma, B Cell Clinical Trials

A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.

NCT ID: NCT00210314 Completed - Lymphoma, B Cell Clinical Trials

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Start date: July 2003
Phase: Phase 2
Study type: Interventional

Aim of the study is to establish in a prospective, randomized clinical trial the activity of primary chemotherapy containing high dose-methotrexate, alone or combined with high dose cytarabine, in patients with primary central nervous system lymphoma

NCT ID: NCT00209014 Terminated - B-Cell Lymphoma Clinical Trials

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

Start date: July 2003
Phase: Phase 2
Study type: Interventional

Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. The purpose of this study is to find out what effects (good and bad) the drug thalidomide has on patients and the lymphoma.

NCT ID: NCT00204659 Completed - Clinical trials for Primary Gastric Diffuse-Large B-Cell Lymphoma

Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma

Start date: March 2003
Phase: Phase 2
Study type: Interventional

The optimal treatment of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) has not yet been defined. In most circumstances, a stomach-conserving approach is favored, but the role of radiotherapy is still a matter of debate. Recently, Rituximab along with full-dose CHOP chemotherapy has been shown to improve the outcome in elderly patients with nodal DLBCL. However, no data are available with such a therapy in patients with PG-DLBCL. Therefore, in March 2003, we initiated an ongoing, prospective, multicenter phase II study in patients with PG-DLBCL with 6 to 8 cycles of Rituximab (R; 375 mg/m2) plus CHOP-21 in order to evaluate the safety and efficacy of this approach.

NCT ID: NCT00201422 Completed - MALT Lymphoma Clinical Trials

Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma

Start date: June 1996
Phase: N/A
Study type: Interventional

To evaluate the therapeutic effectiveness of H. pylori eradication in stage IE & IIE-1 primary low-grade B cell lymphoma of MALT of the stomach

NCT ID: NCT00193505 Completed - Clinical trials for Non-Hodgkins Lymphoma

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Start date: October 2003
Phase: Phase 2
Study type: Interventional

In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.

NCT ID: NCT00193479 Completed - Clinical trials for Non-Hodgkins Lymphoma

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent administration of rituximab it is likely to be as effective as longer programs, and will certainly be better tolerated by this patient group. The addition of maintenance therapy may result in substantial prolongation of remission duration.

NCT ID: NCT00169468 Completed - B Cell Lymphoma Clinical Trials

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the response rate and toxicity of the association R-CHOP with two schedules of administration of Velcade, in B-cell CD 20 + lymphoma patients, aged from 18 to 80 years The goal is to get a response rate at least at what observed with R-CHOP alone and will be evaluates with a sequential test. The other objective is to evaluate the toxicity